Syschem India Limited has announced that promoter Ranjan Jain has sold a portion of his shareholding through open market transactions. The disclosure was submitted to BSE Limited on February 14, 2026, in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Transaction Details

The share sale transaction involved the disposal of 1,60,000 equity shares through open market operations conducted between February 11-13, 2026. The following table summarizes the key transaction parameters:

Shareholding Pattern Changes

The transaction resulted in a reduction of Ranjan Jain's stake in Syschem India Limited. His shareholding position before and after the sale is detailed below:

Company Capital Structure

Syschem India Limited's equity share capital structure remains unchanged following the promoter's share sale:

• Total Equity Share Capital: Rs. 43.51 crores • Number of Equity Shares: 4,35,13,000 shares • Face Value per Share: Rs. 10 • Total Diluted Share Capital: Rs. 56.56 crores (56,56,3000 shares)

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Ranjan Jain, who serves as both Promoter and Director of the company, submitted the required documentation to BSE Limited where Syschem India's shares are listed. The transaction involved only shares carrying voting rights, with no encumbrances, warrants, or convertible securities involved in the sale.

The promoter confirmed that he belongs to the Promoter Group and that all regulatory requirements have been fulfilled in connection with this share disposal transaction.

Syschem India Limited announced exceptional financial results for the quarter ended December 31, 2025, demonstrating remarkable growth across key performance metrics. The pharmaceutical company's Board of Directors approved the unaudited financial results at a meeting held on February 2, 2026, which commenced at 11:00 A.M. and concluded at 3:20 P.M., along with significant expansion plans to capitalize on strong market demand.

Outstanding Q3FY26 Financial Performance

The company delivered impressive quarterly results with substantial year-on-year improvements across all major financial parameters:

The company's revenue growth was driven by strong operational performance, with total income from operations reaching ₹16,164.37 lakhs compared to ₹9,114.22 lakhs in the previous year quarter. Cost management remained effective with total expenses of ₹15,667.85 lakhs, resulting in significantly improved profitability margins.

Strong Nine-Month Performance

For the nine months ended December 31, 2025, Syschem India demonstrated consistent growth momentum:

The nine-month performance showcased the company's ability to maintain growth trajectory throughout the period, with material costs of ₹31,477.08 lakhs and employee benefits expense of ₹708.54 lakhs supporting expanded operations.

Major Plant Expansion Initiative

Responding to tremendous market response for its products, the Board approved a comprehensive expansion of existing manufacturing facilities. The expansion project encompasses multiple strategic components:

The expansion includes addition of new manufacturing units for Amoxicillin and Ampicillin production, along with further expansion of existing CDF units comprising Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. Additionally, the company will expand its Effluent Treatment Plant (ETP) and Multi-Effect Evaporator (MEE) to strengthen environmental compliance and support sustainable operations.

Regulatory Compliance and Corporate Governance

The Board also approved several important corporate governance measures during the meeting. The company adopted a revised Related Party Policy to align with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/135 dated October 13, 2025, subject to Audit Committee approval.

The statutory auditors STAV & CO, Chartered Accountants, conducted a limited review of the financial results and expressed an unmodified conclusion. The financial results were prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and comply with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Regulatory Intimation and Publication

Following regulatory requirements, the company submitted an intimation under Regulation 47(3) read with Schedule III of SEBI Listing Regulations to BSE Limited on February 3, 2026. The intimation confirmed the publication of Q3FY26 unaudited financial results in newspapers including Jansatta (Hindi) and Financial Express on February 3, 2026, as required by regulatory guidelines.

Strategic Outlook

The approved expansion is expected to significantly enhance Syschem India's manufacturing capacity, operational efficiency, and environmental management capabilities. With the company's strong financial performance providing a solid foundation and the pharmaceutical sector showing robust demand, the expansion positions Syschem India for sustained growth in the coming periods. The December 2026 commissioning timeline indicates the company's commitment to rapid capacity enhancement while maintaining quality standards.